Toll-like receptor signaling modulates critical immunomodulatory NFkB signaling and is a promising target for treating cardiovascular disease [126–128] (clinicaltrials.gov ID# NCT04734548). The gene discussed is NFKB1; the disease is cardiovascular disorder.